38 studies 89 arms 3923 patients ▪ lack of control group unless Potentially relevant CTs identified and screened for retrieval (N=115) RCTs included in the analysis Short term CTs: duration ≤12 weeks (N=38) Potentially appropriate RCTs to be Included in the analysis (N=64) RCTs excluded because of: ▪ design (crossover, combination, retrospective, discontinuation) (N=8) ▪ lack of control group unless duration ≥ 13 weeks (N=26) ▪ other interests (young adults, pharmaco/vigilance or kinetics (N=9) ▪ Review or meta-analysis (N=6) ▪ Arm with N < 9 (N=2) RCTs excluded from analysis because of data reported elsewhere (N=9) Long term CTs: duration ≥13 weeks (N=16) 38 studies 89 arms 3923 patients Incomplete reporting of all variables of interest (N=1)

Weight gain : compared to placebo 29 studies 65 arms - 3204 patients Weight gain : compared to placebo kg Arm (N) Patient (N) 4 228 61 8 606 7 413 10 351 16 691 16 854 Placebo

Patients with significant weight gain 24 studies 57 arms - 3229 patients Patients with significant weight gain Arm (N) Patient (N) 3 212 57 8 612 5 345 297 15 759 15 947 Placebo

12 studies 32 arms - 1511 patients Arm (N) Patient (N) 1 12 8 606 3 68 324 5 131 7 370 Placebo

10 studies 27 arms - 1784 patients mg/dl Arm (N) Patient (N) 3 212 243 5 371 4 259 187 8 512 Placebo

10 studies 27 arms - 1784 patients mg/dl Arm (N) Patient (N) 3 212 243 5 371 4 259 187 8 512 Placebo

10 studies 27 arms - 1655 patients mg/dl Arm (N) Patient (N) 3 212 243 6 388 152 4 187 8 473 Placebo

somnolence/sedation : compared to placebo 29 studies 64 arms - 3305 patients somnolence/sedation : compared to placebo Arm (N) Patient (N) 7 228 1 12 8 612 404 254 17 775 19 1020 Placebo

26 studies 61 arms - 3209 patients Arm (N) Patient (N) 3 212 8 612 6 362 109 21 938 17 976 Placebo

Risperidone Olanzapine Quetiapine Aripiprazole Clozapine Ziprasidone  Weight ++ ++++ +++ +  Glucose +/- ?  Cholesterol  Trigly  Prolactin Somnolence Extra-pyramidal 0?